Astellas Keeps Chinese Collab Train Chugging With $1.5B+ Bet for Claudin ADC

At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric cancer and pancreatic cancer.